Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TerrAscendTSNDF -0.08%44 EV-to-OCF is 17.04 as of Aug. 08, 2026. GuruFocus rates TSNDF with a GF Score™ of 44/100 and a GF Value™ of $0.99 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,007 Drug Manufacturers companies, TerrAscend ranks worse than 64.75% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, TerrAscend's Enterprise Value is $375.1 Mil.
TerrAscend's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $22.0 Mil. Therefore, TerrAscend's EV-to-OCF for today is 17.04.
The historical rank and industry rank for TerrAscend's EV-to-OCF or its related term are showing as below:
TSNDF'
s EV-to-OCF Range Over the Past 10 Years
Min: -727.77 Med: -12.32 Max: 325.8
Current: 17.04
During the past 10 years, the highest EV-to-OCF of TerrAscend was 325.80. The lowest was -727.77. And the median was -12.32.
TSNDF's EV-to-OCF is ranked worse than 64.75% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 10.87
vs TSNDF: 17.04
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
TerrAscend's share price for today is $0.52129.
TerrAscend's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.270.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
TerrAscend EV-to-OCF Related Terms
TerrAscend EV-to-OCF Historical Data
* Premium members only.
The historical data trend for TerrAscend's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, TerrAscend's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TerrAscend EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TerrAscend's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where TerrAscend's EV-to-OCF falls into.
TerrAscend's current Enterprise Value is $375.1 Mil.
TerrAscend's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $22.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TerrAscend (TSNDF) has a EV-to-OCF of 17.04 as of Aug. 08, 2026. According to the industry distribution chart, TerrAscend ranks #652 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 64.7%.
Is TerrAscend's EV-to-OCF too high?
TerrAscend's current EV-to-OCF is 17.04. The Drug Manufacturers industry median EV-to-OCF is 10.87. TerrAscend's value of 17.04 is 56.8% above this industry median. Based on the distribution chart, TerrAscend ranks #652 out of 1007 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, TerrAscend has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TerrAscend's EV-to-OCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, TerrAscend ranks #652 out of 1007 companies for EV-to-OCF. This places TerrAscend in the lower half of its industry. The industry median EV-to-OCF is 10.87. TerrAscend's value of 17.04 is 56.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.87, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TerrAscend's current EV-to-OCF of 17.04 is 56.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TerrAscend's current EV-to-OCF is 17.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TerrAscend stock overvalued right now?
Based on GuruFocus' analysis, TerrAscend (TSNDF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.99, compared to a current price of $0.52 — trading 47.3% below its estimated fair value. The current EV-to-OCF is 17.04 and 56.8% above the Drug Manufacturers industry median of 10.87. TerrAscend's overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For TerrAscend (TSNDF), the current EV-to-OCF is 17.04 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TerrAscend (TSNDF) Overvalued in 2026?
Based on GuruFocus' analysis, TerrAscend stock appears to be undervalued.
The current stock price of $0.52 is trading 47.3% below its estimated GF Value™ of $0.99.
GuruFocus considers TerrAscend to be Possible Value Trap.
Key valuation signals for TSNDF:
EV-to-OCF: 17.04
GF Value™: $0.99 vs. price of $0.52 (47.3% below fair value)
Industry Position: 56.8% above the Drug Manufacturers median (#652 of 1007)
No single metric tells the full story. See the TSNDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TerrAscend Corp is a company focused on creating and delivering cannabis products and services that meet the evolving needs of its patients. It also provides education and support programs to physicians and patients through healthcare professionals. In addition, the firm operates in California, Maryland, New Jersey, and Pennsylvania, with retail operations in Ohio and Canada. It operates The Apothecarium and other dispensary retail locations as well as scaled cultivation, processing, and manufacturing facilities in its core markets. The firm has one operating segment, being the cultivation, production, and sale of cannabis products, with subsidiaries located in Canada and the United States. The company generates key revenue from the United States.
44GF Score
Get the complete analysis for TSNDF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSNDF has been successfully added to your 
